PD1/PD-L1 inhibitors (of which the first validated agents were pembrolizumab and nivolumab) have been shown to improve survival rates among patients with various tumour types, including melanoma, lung, head and neck, and bladder cancers. The gene discussed is CD274; the disease is neoplasm.